Keymed Biosciences: No Share Capital Changes in May 2026, Public Float Remains Sufficient

Bulletin Express06-02

Keymed Biosciences Inc. released its Monthly Return for the period ended 31 May 2026, confirming that equity structure and public float remained stable throughout the month.

Authorised Share Capital • The company’s authorised share base stayed at 500.00 million ordinary shares, each with a par value of USD 0.0001, representing total authorised capital of USD 50,000. No increase or decrease was recorded during May.

Issued Shares and Treasury Position • Issued shares at month-end were unchanged at 298.74 million. • The firm held no treasury shares, leaving total issued share count also at 298.74 million.

Public Float Compliance • Keymed Biosciences affirmed compliance with the Main Board’s minimum 25 % public float requirement as of 31 May 2026.

Capital-Related Instruments • The filing recorded no activity in share options, warrants, convertible securities or other share-issuance agreements during the month.

Management Sign-off • The return was submitted on 02 June 2026 by Executive Director Dr. Bo Chen.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154670147?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 17:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154670147","market":"hk","top_or_hot":-1,"title":"Keymed Biosciences: No Share Capital Changes in May 2026, Public Float Remains Sufficient","media":"Bulletin Express","content":"<p>Keymed Biosciences Inc. released its Monthly Return for the period ended 31 May 2026, confirming that equity structure and public float remained stable throughout the month.</p>\n<p>Authorised Share Capital  \n• The company’s authorised share base stayed at 500.00 million ordinary shares, each with a par value of USD 0.0001, representing total authorised capital of USD 50,000. No increase or decrease was recorded during May.</p>\n<p>Issued Shares and Treasury Position  \n• Issued shares at month-end were unchanged at 298.74 million.  \n• The firm held no treasury shares, leaving total issued share count also at 298.74 million.</p>\n<p>Public Float Compliance  \n• Keymed Biosciences affirmed compliance with the Main Board’s minimum 25 % public float requirement as of 31 May 2026.</p>\n<p>Capital-Related Instruments  \n• The filing recorded no activity in share options, warrants, convertible securities or other share-issuance agreements during the month.</p>\n<p>Management Sign-off  \n• The return was submitted on 02 June 2026 by Executive Director Dr. Bo Chen.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Biosciences: No Share Capital Changes in May 2026, Public Float Remains Sufficient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Biosciences: No Share Capital Changes in May 2026, Public Float Remains Sufficient\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-02 17:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Keymed Biosciences Inc. released its Monthly Return for the period ended 31 May 2026, confirming that equity structure and public float remained stable throughout the month.</p>\n<p>Authorised Share Capital  \n• The company’s authorised share base stayed at 500.00 million ordinary shares, each with a par value of USD 0.0001, representing total authorised capital of USD 50,000. No increase or decrease was recorded during May.</p>\n<p>Issued Shares and Treasury Position  \n• Issued shares at month-end were unchanged at 298.74 million.  \n• The firm held no treasury shares, leaving total issued share count also at 298.74 million.</p>\n<p>Public Float Compliance  \n• Keymed Biosciences affirmed compliance with the Main Board’s minimum 25 % public float requirement as of 31 May 2026.</p>\n<p>Capital-Related Instruments  \n• The filing recorded no activity in share options, warrants, convertible securities or other share-issuance agreements during the month.</p>\n<p>Management Sign-off  \n• The return was submitted on 02 June 2026 by Executive Director Dr. Bo Chen.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1154670147","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154670147","pubTimestamp":1780391117,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Keymed Biosciences Inc. released its Monthly Return for the period ended 31 May 2026, confirming that equity structure and public float remained stable throughout the month. Authorised Share Capital...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"康盟生物：2026年5月股本无变动公众持股量保持充足","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"Keymed Biosciences Inc. released its Monthly Return for the period ended 31 May 2026, confirming that equity structure and public float remained stable throughout the month.\nAuthorised Share Capital  \n• The company’s authorised share base stayed at 500.00 million ordinary shares, each with a par value of USD 0.0001, representing total authorised capital of USD 50,000. No increase or decrease was recorded during May.\nIssued Shares and Treasury Position  \n• Issued shares at month-end were unchanged at 298.74 million.  \n• The firm held no treasury shares, leaving total issued share count also at 298.74 million.\nPublic Float Compliance  \n• Keymed Biosciences affirmed compliance with the Main Board’s minimum 25 % public float requirement as of 31 May 2026.\nCapital-Related Instruments  \n• The filing recorded no activity in share options, warrants, convertible securities or other share-issuance agreements during the month.\nManagement Sign-off  \n• The return was submitted on 02 June 2026 by Executive Director Dr. Bo Chen.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154670147","isCrawlerRequest":true}